Reflections

Notes on AI, evidence, and market access

Expert insights on healthcare AI, HEOR, HTA, and the science of getting therapies to patients faster.

Latest · May 25, 2026Calibrated Confidence over Active Learning: Methodological Foundations for Reliable Abstract ScreeningTwo paradigms compete to accelerate abstract screening: active-learning rankers and autonomous, confidence-calibrated agentic AI. The published evidence reframes the choice as one of scientific reliability, reproducibility, and risk transparency.Mara Rada · 5 min read

From the article"Active-learning stopping rules should be applied cautiously — the first systematic empirical test shows each one fails. A platform that produces a deterministic, calibrated decision for every record can meet the reproducibility standard systematic review methodology requires."

AI & HTA · July 5, 2026Simulating the Committee: How Loon Waters™ Predicts Reimbursement Recommendations — and Their ConditionsMara Rada · 7 min read Pricing · January 5, 2026Navigating Convergent Pricing Headwinds: A Strategic Assessment of Policy Risk and Value Defence in the U.S. Biopharmaceutical MarketMara Rada · 9 min read Compliance · November 24, 2025Methodological Compliance for The Use of Loon AI® in Evidence Synthesis: How Loon’s Confidence Calibration Meets NICE, CDA-AMC, and ISPOR Auditing RequirementsMara Rada · 5 min read Policy · August 3, 2025US Pharmaceutical Pricing Ultimatum and the Evolving Drug Value Assessment LandscapeDr. Ghayath Janoudi · 7 min read AI & HTA · July 5, 2025Revolutionizing Health Technology Assessment: How AI is Transforming Market Access in 2024Loon Team · 4 min read Systematic reviews · May 10, 2025Making Systematic Reviews Feasible: Evidence-Based Automation Through Validated AIDr. Ghayath Janoudi · 6 min read HTA · February 15, 2025The Future of HTA Submissions: Automated Evidence GenerationGhayath Janoudi · 7 min read AI & HTA · February 8, 2025AI Integration in Health Technology Assessment: Evidence from Early Adopters in 2025Loon Team · 8 min read Biopharma · January 27, 2025Hidden Risks in Biopharma: Clinical and Economic EvidenceMara Rada · 6 min read Market access · December 31, 2024AI Drug Discovery's $60 Billion Reality Check: Hype, Failures, and the Market Access BlindspotMara Rada · 15 min read Loon Lens™ · December 10, 2024Loon Lens™: Autonomous AI Agents for Literature Screening in Systematic ReviewsDr. Ghayath Janoudi · 8 min read Compliance · December 10, 2024Loon's Compliance with the NICE Position, CDA-AMC Guidelines, and ISPOR ELEVATE-AI LLMs Framework on The Use of AI in Evidence SynthesisLoon Team · 10 min read Market access · December 5, 2024Systematic Risk Assessment in Pharmaceutical Market Access: An Evidence-Based AnalysisMara Rada · 8 min read Validation · November 20, 2024AI Literature Screening: Evidence-Based Validation for Systematic Review AutomationDr. Ghayath Janoudi · 7 min read Multi-agent AI · September 20, 2024Building the Next Generation of HEOR: Loon's Multi-Agent AI ArchitectureDr. Ghayath Janoudi · 7 min read Clinical discovery · September 20, 2024Augmented Intelligence in Clinical Discovery: Hypertensive Disorders of PregnancyDr. Ghayath Janoudi · 7 min read Clinical discovery · August 15, 2024How Case Reports & Series Generate Clinical Discoveries in PreeclampsiaDr. Ghayath Janoudi · 6 min read Clinical discovery · July 10, 2024Outlier Analysis: Accelerating Clinical Discovery & BreakthroughDr. Ghayath Janoudi · 7 min read Keynote · June 15, 2024The 'Why' Behind AI: Keynote from Innovation GatheringDr. Ghayath Janoudi · 8 min read